Christopher Waddick
Vermögen: 165 798 $ am 31.05.2026
Vermögen: 165 798 $ am 31.05.2026
Christopher J.
Waddick is Chief Financial Officer, Secretary & Director at Cardiol Therapeutics, Inc. since 2022, President & Chief Financial Officer at Active Energy, Inc. since 2013, and President at Nrj Consulting, Inc. since 2009.
Formerly, Mr. Waddick was Chief Financial & Executive Officer at Vasogen, Inc. from 2007 to 2009.
Education includes an MBA from York University and an undergraduate degree from Wilfrid Laurier University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 30.12.2025 | 135’900 ( 0.12% ) | 165 798 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| CARDIOL THERAPEUTICS INC. | Finanzdirektor/CFO | 16.08.2018 |
Active Energy, Inc.
Active Energy, Inc. Electric UtilitiesUtilities Supplies natural gas and electricity | Finanzdirektor/CFO | 01.01.2013 |
Nrj Consulting, Inc. | Präsident | 01.11.2009 |
| Unternehmen | Position | Ende |
|---|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures drugs to treat cardiovascular and neurodegenerative disorders | Vorstandsvorsitzender | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 6 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures drugs to treat cardiovascular and neurodegenerative disorders | Health Technology |
York University
York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wilfrid Laurier University
Wilfrid Laurier University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Active Energy, Inc.
Active Energy, Inc. Electric UtilitiesUtilities Supplies natural gas and electricity | Utilities |
Cardiol Therapeutics, Inc.
Cardiol Therapeutics, Inc. BiotechnologyHealth Technology Operates as a life sciences company that researches and develops antifibrotic and anti-inflammatory therapy for the treatment of cardiovascular disease | Health Technology |
Nrj Consulting, Inc. |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen